{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:47:32Z","timestamp":1794016052707,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Graduate Education Innovation Project at Sun Yat-sen University in 2024","award":["02300-12240001"],"award-info":[{"award-number":["02300-12240001"]}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["242301420078"],"award-info":[{"award-number":["242301420078"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Nos.U20A20369"],"award-info":[{"award-number":["Nos.U20A20369"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Science and Technology Program","award":["KQTD20190929173853397"],"award-info":[{"award-number":["KQTD20190929173853397"]}]},{"name":"\"Pearl River Talent Plan\" Innovation and Entrepreneurship Team Project of Guangdong Province","award":["2019ZT08Y464"],"award-info":[{"award-number":["2019ZT08Y464"]}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2022B1515120085"],"award-info":[{"award-number":["2022B1515120085"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-03955-y","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T08:42:14Z","timestamp":1739263334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chidamide functions as a VISTA\/PSGL-1 blocker for cancer immunotherapy"],"prefix":"10.1007","volume":"74","author":[{"given":"Xiaoshuang","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuman","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghua","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"17","key":"3955_CR1","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy[J]. J Clin Oncol 33(17):1974\u20131982","journal-title":"J Clin Oncol"},{"issue":"9","key":"3955_CR2","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran MA, Montalvo W, Yagita H et al (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors[J]. Proc Natl Acad Sci U S A 107(9):4275\u20134280","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3955_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V et al (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers[J]. Exp Mol Med 50(12):1\u201311","journal-title":"Exp Mol Med"},{"issue":"17","key":"3955_CR4","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","volume":"26","author":"B Li","year":"2019","unstructured":"Li B, Chan HL, Chen P (2019) Immune checkpoint inhibitors: basics and challenges[J]. Curr Med Chem 26(17):3009\u20133025","journal-title":"Curr Med Chem"},{"key":"3955_CR5","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S (2023) Cancer immunotherapies: advances and bottlenecks[J]. Front Immunol 14:1212476","journal-title":"Front Immunol"},{"key":"3955_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40425-016-0190-5","volume":"4","author":"J Deng","year":"2016","unstructured":"Deng J, Le Mercier I, Kuta A et al (2016) A new VISTA on combination therapy for negative checkpoint regulator blockade[J]. J Immunother Cancer 4:86","journal-title":"J Immunother Cancer"},{"issue":"3","key":"3955_CR7","first-page":"198","volume":"21","author":"X Sui","year":"2023","unstructured":"Sui X, Niu X, Zhou X et al (2023) Peptide drugs: a new direction in cancer immunotherapy[J]. Cancer Biol Med 21(3):198\u2013203","journal-title":"Cancer Biol Med"},{"issue":"1","key":"3955_CR8","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1038\/s41467-020-17756-7","volume":"11","author":"H Wu","year":"2020","unstructured":"Wu H, Estrella V, Beatty M et al (2020) T-cells produce acidic niches in lymph nodes to suppress their own effector functions[J]. Nat Commun 11(1):4113","journal-title":"Nat Commun"},{"issue":"1","key":"3955_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M et al (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4[J]. Mol Cancer 18(1):155","journal-title":"Mol Cancer"},{"issue":"7779","key":"3955_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","volume":"574","author":"RJ Johnston","year":"2019","unstructured":"Johnston RJ, Su LJ, Pinckney J et al (2019) VISTA is an acidic pH-selective ligand for PSGL-1[J]. Nature 574(7779):565\u2013570","journal-title":"Nature"},{"issue":"1","key":"3955_CR11","doi-asserted-by":"publisher","first-page":"15171","DOI":"10.1038\/s41598-020-71519-4","volume":"10","author":"N Mehta","year":"2020","unstructured":"Mehta N, Maddineni S, Kelly RL et al (2020) An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA[J]. Sci Rep 10(1):15171","journal-title":"Sci Rep"},{"issue":"14","key":"3955_CR12","doi-asserted-by":"publisher","first-page":"1086102","DOI":"10.3389\/fimmu.2023.1086102","volume":"20","author":"AS Martin","year":"2023","unstructured":"Martin AS, Molloy M, Ugolkov A et al (2023) VISTA expression and patient selection for immune-based anticancer therapy. Front Immunol 20(14):1086102","journal-title":"Front Immunol"},{"issue":"1","key":"3955_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12935-023-03116-0","volume":"23","author":"N Shekari","year":"2023","unstructured":"Shekari N, Shanehbandi D, Kazemi T et al (2023) VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy[J]. Cancer Cell Int 23(1):265","journal-title":"Cancer Cell Int"},{"key":"3955_CR14","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.semcancer.2021.08.008","volume":"86","author":"E Im","year":"2022","unstructured":"Im E, Sim DY, Lee HJ et al (2022) Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy[J]. Semin Cancer Biol 86:1066\u20131075","journal-title":"Semin Cancer Biol"},{"issue":"18","key":"3955_CR15","doi-asserted-by":"publisher","first-page":"11900","DOI":"10.1021\/acs.jmedchem.2c00803","volume":"65","author":"S Zheng","year":"2022","unstructured":"Zheng S, Zhang K, Zhang X et al (2022) Development of inhibitors targeting the V-domain Ig suppressor of T cell activation signal pathway[J]. J Med Chem 65(18):11900\u201311912","journal-title":"J Med Chem"},{"issue":"1","key":"3955_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","volume":"4","author":"PG Sasikumar","year":"2021","unstructured":"Sasikumar PG, Sudarshan NS, Adurthi S et al (2021) PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy[J]. Commun Biol 4(1):699","journal-title":"Commun Biol"},{"issue":"1","key":"3955_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s42003-021-02381-x","volume":"4","author":"J Pan","year":"2021","unstructured":"Pan J, Chen Y, Zhang Q et al (2021) Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA[J]. Commun Biol 4(1):906","journal-title":"Commun Biol"},{"issue":"5","key":"3955_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/biom11050706","volume":"11","author":"X Zhou","year":"2021","unstructured":"Zhou X, Jiao L, Qian Y et al (2021) Repositioning azelnidipine as a dual inhibitor targeting CD47\/SIRP\u03b1 and TIGIT\/PVR pathways for cancer immuno-therapy[J]. Biomolecules. 11(5):706","journal-title":"Biomolecules"},{"issue":"5","key":"3955_CR19","first-page":"706","volume":"11","author":"C Chen","year":"2022","unstructured":"Chen C, Sui X, Ning H et al (2022) Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression[J]. J Immunother Cancer 11(5):706","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3955_CR20","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s11427-023-2472-4","volume":"67","author":"X Zhou","year":"2024","unstructured":"Zhou X, Li Y, Zhang X et al (2024) Hemin blocks TIGIT\/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy[J]. Sci China Life Sci. 67(5):996\u20131009","journal-title":"Sci China Life Sci."},{"issue":"1","key":"3955_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W et al (2017) Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China[J]. J Hematol Oncol 10(1):69","journal-title":"J Hematol Oncol"},{"issue":"11","key":"3955_CR22","doi-asserted-by":"publisher","first-page":"11255","DOI":"10.21037\/apm-21-1139","volume":"10","author":"Y Meng","year":"2021","unstructured":"Meng Y, Jin J, Gong C et al (2021) Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer[J]. Ann Palliat Med 10(11):11255\u201311264","journal-title":"Ann Palliat Med"},{"issue":"1","key":"3955_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s12916-022-02598-5","volume":"20","author":"P Zhang","year":"2022","unstructured":"Zhang P, Du Y, Bai H et al (2022) Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors[J]. BMC Med 20(1):435","journal-title":"BMC Med"},{"issue":"10","key":"3955_CR24","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41419-021-04187-5","volume":"12","author":"K Xue","year":"2021","unstructured":"Xue K, Wu JC, Li XY et al (2021) Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed\/refractory B-cell lymphoma[J]. Cell Death Dis 12(10):900","journal-title":"Cell Death Dis"},{"key":"3955_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jconrel.2021.04.036","volume":"334","author":"W Li","year":"2021","unstructured":"Li W, Zhu X, Zhou X et al (2021) An orally available PD-1\/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy[J]. J Control Release 334:376\u2013388","journal-title":"J Control Release"},{"issue":"11","key":"3955_CR26","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1016\/j.apsb.2023.08.003","volume":"13","author":"X Niu","year":"2023","unstructured":"Niu X, Wu M, Li G et al (2023) Identification and optimization of peptide inhibitors to block VISTA\/PSGL-1 interaction for cancer immunotherapy[J]. Acta Pharm Sin B 13(11):4511\u20134522","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"3955_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","volume":"42","author":"L Yuan","year":"2021","unstructured":"Yuan L, Tatineni J, Mahoney KM et al (2021) VISTA: a mediator of quiescence and a promising target in cancer immunotherapy[J]. Trends Immunol 42(3):209\u2013227","journal-title":"Trends Immunol"},{"issue":"12","key":"3955_CR28","doi-asserted-by":"publisher","first-page":"1014904","DOI":"10.3389\/fonc.2022.1014904","volume":"10","author":"S Huang","year":"2022","unstructured":"Huang S, Zhao Y, Liao P et al (2022) Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma[J]. Front Oncol 10(12):1014904","journal-title":"Front Oncol"},{"issue":"1","key":"3955_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2326-6066.CIR-22-0116","volume":"11","author":"E Schaafsma","year":"2023","unstructured":"Schaafsma E, Croteau W, ElTanbouly M et al (2023) VISTA targeting of T-cell quiescence and myeloid suppression overcomes adaptive resistance[J]. Cancer Immunol Res 11(1):38\u201355","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"3955_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00280-023-04609-5","volume":"93","author":"Y Tonozuka","year":"2024","unstructured":"Tonozuka Y, Tanaka H, Nomura K et al (2024) The combination of brentuximab vedotin and Chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis[J]. Cancer Chemother Pharmacol 93(2):137\u2013149","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3955_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cmet.2020.10.021","volume":"33","author":"H Lv","year":"2020","unstructured":"Lv H, Lv G, Chen C et al (2020) NAD+ metabolism maintains inducible PD-L1 expression to drive tumor immune evasion[J]. Cell Metab 33(1):110\u2013127","journal-title":"Cell Metab"},{"issue":"10","key":"3955_CR32","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s00277-023-05359-3","volume":"102","author":"C Gong","year":"2023","unstructured":"Gong C, Wu J, Song W et al (2023) Enhanced efficacy of combined fluzoparib and Chidamide targeting in natural killer\/T-cell lymphoma[J]. Ann Hematol 102(10):2845\u20132855","journal-title":"Ann Hematol"},{"issue":"9","key":"3955_CR33","doi-asserted-by":"publisher","first-page":"e1469594","DOI":"10.1080\/2162402X.2018.1469594","volume":"7","author":"L Wang","year":"2018","unstructured":"Wang L, Jia B, Claxton DF et al (2018) VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML[J]. Oncoimmunology 7(9):e1469594","journal-title":"Oncoimmunology"},{"issue":"3","key":"3955_CR34","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1084\/jem.20100619","volume":"208","author":"L Wang","year":"2011","unstructured":"Wang L, Rubinstein R, Lines JL et al (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses[J]. J Exp Med 208(3):577\u2013592","journal-title":"J Exp Med"},{"issue":"2","key":"3955_CR35","doi-asserted-by":"publisher","first-page":"e003382","DOI":"10.1136\/jitc-2021-003382","volume":"10","author":"D Thakkar","year":"2022","unstructured":"Thakkar D, Paliwal S, Dharmadhikari B et al (2022) Rationally targeted anti-VISTA antibody that blockades the C-C\u2019 loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner[J]. J Immunother Cancer 10(2):e003382","journal-title":"J Immunother Cancer"},{"issue":"14","key":"3955_CR36","doi-asserted-by":"publisher","first-page":"1311658","DOI":"10.3389\/fimmu.2023.1311658","volume":"12","author":"S Iadonato","year":"2023","unstructured":"Iadonato S, Ovechkina Y, Lustig K et al (2023) A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors[J]. Front Immunol 12(14):1311658","journal-title":"Front Immunol"},{"issue":"1","key":"3955_CR37","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1038\/s41467-024-47256-x","volume":"15","author":"T Thisted","year":"2024","unstructured":"Thisted T, Smith FD, Mukherjee A et al (2024) VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response[J]. Nat Commun 15(1):2917","journal-title":"Nat Commun"},{"issue":"8","key":"3955_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs[J]. Nat Rev Drug Discov 3(8):673\u2013683","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3955_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","volume":"39","author":"R Chen","year":"2020","unstructured":"Chen R, Zhang M, Zhou Y et al (2020) The application of histone deacetylases inhibitors in glioblastoma[J]. J Exp Clin Cancer Res 39(1):138","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"3955_CR40","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/j.1582-4934.2010.01144.x","volume":"15","author":"DR Bhandari","year":"2011","unstructured":"Bhandari DR, Seo KW, Jung JW et al (2011) The regulatory role of c-MYC on HDAC2 and PcG expression in human multipotent stem cells[J]. J Cell Mol Med 15(7):1603\u20131614","journal-title":"J Cell Mol Med"},{"issue":"11","key":"3955_CR41","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","volume":"19","author":"SJ Hogg","year":"2020","unstructured":"Hogg SJ, Beavis PA, Dawson MA et al (2020) Targeting the epigenetic regulation of antitumour immunity[J]. Nat Rev Drug Discov 19(11):776\u2013800","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"3955_CR42","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1158\/2159-8290.CD-23-0225","volume":"13","author":"A Davies","year":"2023","unstructured":"Davies A, Zoubeidi A, Beltran H et al (2023) The transcriptional and epigenetic landscape of cancer cell lineage plasticity[J]. Cancer Discov 13(8):1771\u20131788","journal-title":"Cancer Discov"},{"issue":"3","key":"3955_CR43","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","volume":"108","author":"S Rai","year":"2023","unstructured":"Rai S, Kim WS, Ando K et al (2023) Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results[J]. Haematologica 108(3):811\u2013821","journal-title":"Haematologica"},{"key":"3955_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.819714","author":"X Li","year":"2022","unstructured":"Li X, Yuan X, Wang Z et al (2022) Chidamide reverses fluzoparib resistance in triple-negative breast cancer cells[J]. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.819714","journal-title":"Front Oncol"},{"issue":"13","key":"3955_CR45","doi-asserted-by":"publisher","first-page":"835103","DOI":"10.3389\/fimmu.2022.835103","volume":"2","author":"J Wang","year":"2022","unstructured":"Wang J, Su N, Fang Y et al (2022) Comparison of chemotherapy combined with Chidamide versus chemotherapy in the frontline treatment for peripheral T-cell lymphoma[J]. Front Immunol 2(13):835103","journal-title":"Front Immunol"},{"issue":"4","key":"3955_CR46","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1007\/s13577-023-00919-1","volume":"36","author":"L Yin","year":"2023","unstructured":"Yin L, Zhang Q, Xie S et al (2023) HDAC inhibitor Chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway[J]. Hum Cell 36(4):1564\u20131577","journal-title":"Hum Cell"},{"issue":"4","key":"3955_CR47","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ijrobp.2022.04.001","volume":"113","author":"Y Chai","year":"2022","unstructured":"Chai Y, Chen B, Qi F et al (2022) First-line chemoradiation with or without Chidamide (tucidinostat) in patients with intermediate- and high-risk early-stage extranodal nasal-type natural killer\/T-cell lymphoma: a randomized phase 2 study in China[J]. Int J Radiat Oncol Biol Phys 113(4):833\u2013844","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"3955_CR48","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","volume":"30","author":"F Wang","year":"2024","unstructured":"Wang F, Jin Y, Wang M et al (2024) Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial[J]. Nat Med 30(4):1035\u20131043","journal-title":"Nat Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03955-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-03955-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03955-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:24:42Z","timestamp":1741001082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-03955-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3955"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-03955-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"104"}}